A life sciences investment firm with a focus on supporting emerging biotechnology companies closed a new fund in 2022 dedicated to private investments. The firm focuses exclusively in biopharmaceuticals and looks to make Seed through Series B investments with a typical check size averaging $10M. The firm typically makes investments in the form of equity but will do convertible notes for some Seed stage investments. The firm looks to make investments in the US and Europe.

The firm invests exclusively in therapeutics but is subsector and indication agnostic and open all modalities with a particular focus in cell therapy, RNA therapy, small molecules and antibodies. The firm is open to preclinical companies.

The firm looks for established management teams with the CEO in place. The firm likes to see teams that are credible but don’t necessarily need prior experience starting a company. The firm likes to follow teams as they advance. The firm is open to both leading and coinvesting and seeks a board seat in either circumstance.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in China with over US$9.5 billion in total managed assets in the areas of technology and consumer (T&C) and healthcare has offices located in Shanghai, Beijing, Suzhou and Hong Kong. In China, the firm has invested in over 200 healthcare companies, that span most sectors of life sciences from innovative drugs, medical devices, diagnostics, and healthcare services. The firm invests primarily in US and China-based companies.

The firm is open to many sectors in the life science space – innovative drugs, medical devices, diagnostics, and healthcare services. The firm is most interested in breakthrough products and technologies that address a large unmet need. The firm is also interested in enabling technologies for drug discovery and development, and other healthcare-related technologies in the “digital-health” space.

The firm is seeking to invest in companies with novel ideas and technology and experienced and passionate management. The firm’s team is “hands-on” and typically assumes a board seat after an investment. In general, the firm invests globally and prefers companies that have upside opportunities in China and can leverage the firm’s China network and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm based in the US is focused on companies in the healthcare field with a preference for innovative technology-based companies in Medtech, Diagnostics, and Digital Health. For medical devices, the firm will invest in both PMA and 510k devices and prefers to see some clinical validation. The firm is stage agnostic but most often first invests $3-8M in Series A-C and reserves funds for follow-on investments. Most of the firm’s investments have been in the US and Israel, but the firm is open to investing globally.

The firm invests in companies with medical device, diagnostics and digital health technologies, focusing on innovative companies that can revolutionize their space. The firm favors technology-based products, such as genomics-based diagnostics or high-tech medical devices. Within digital health, the firm is fairly open, but has an interest in companies developing tools for clinical trials and other products developed for payer networks or Big Pharma. The firm is also interested in digital health technologies for hard-to-reach patient populations, such as those suffering from mental health disorders or substance abuse. While fairly opportunistic with regards to indication, the firm is particularly interested in technologies in the COPD, pulmonary hypertension, orthopedic and neurological space as well as products using ablation to treat pain.

The firm wants to see a strong CEO and Board when making investments. While often a not a lead investor, the firm is very active and will frequently take a Board seat after investing. The firm is looking to lead more investments when investing from their third fund.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A private investment firm based in the US launched a fund about 10 years ago to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The firm focuses on early-stage digital health projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor, and can act as either a lead or co-investor. The firm prefers to lead investments in seed rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A family office investment firm is focused on early-stage Biotech/Medtech investments primarily in Switzerland. The firm’s biggest investment in a single company is CHF 5M thus far, but the size of investment could vary. The firm looks for companies located around the globe, with a preference in Switzerland or Europe. The firm is actively seeking new investment opportunities.

The firm looks to invest 70% in Therapeutics, 10% in Medical Devices, 10% Digital Health and 10% in Diagnostics. In Therapeutic areas, the firm might invest half in early-stage and another half in later-stage. The firm is opportunistic in indications and willing to consider orphan indications. The firm seeks technologies that could fill unmet medical needs.

The firm has no specific requirements on companies. The firm currently acts as lead investors for two companies, and has represented in five boards. The firm might take a board seat depends on applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A strategic healthcare venture investment representing multiple health systems as LPs has decades of investment experience. The firm makes equity investments into early- to late-stage companies with additional capital reserved for follow on financings. The firm prefers to invest in USA-based companies.

The firm is currently looking for new opportunities in the Medical Device, Diagnostic, Healthcare IT and Healthcare Services spaces. The firm considers all classes of medical devices and focuses on device companies in the pre-commercial stage. The firm has a preference for platform technologies and companies whose products are already commercialized. The firm’s Healthcare IT and Healthcare Services investments are typically in the commercial or growth stages. The firm invests in privately held healthcare companies. The firm looks to invest in companies with a strong management team who can demonstrate relevant experience, depth and capability to build and scale the business and attract customers. The firm typically requests a Board seat or Board observation rights for each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A firm with multiple offices throughout Western Europe makes biotech and medtech investments from an evergreen fund. The firm typically makes initial investments of EUR 7-15M at the Series A or B stage, and may commit EUR 25M over the life of an investment. The firm invests mainly across Europe, and aims to make at least 4 life science investments per year, with 80% in the therapeutics space.

The firm invests across the biotech and medtech sectors. Within the biotech sector, the firm prefers to invest in platform technologies, multi asset and single asset companies, and will invest as early as the preclinical stage. The firm will consider any therapeutic area, and has an interest in orphan drugs. The firm prefers opportunities that do not require very large clinical trials. For medical devices, the firm prefers to invest in companies with products with a global potential, that are close to acquiring a CE Mark and/or US approval and that are preparing commercialization. The firm is also interested in enabling technologies such as next-gen PCR and lab equipment. The firm does not invest in company-creation opportunities: the firm prefers to work with companies that already have high-quality management teams that have proven themselves through past success in the life science industry, and who have a strong network within the industry. The firm also considers the company’s capital efficiency, future capital needs, and the strength of the company’s prior investment syndicate. The firm prefers to lead or co-lead investments, and is a highly active investor at a portfolio company’s board level.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.